Experience

We are advising RB on the acquisition

We advised Charles River on the acquisition of a cell and gene therapy contract development and manufacturing organization

We are advising Cornell Capital on the acquisition

Davis Polk is advising Goldman Sachs & Co. LLC and Lazard Frères & Co. LLC as financial advisers to ImmunityBio, Inc. in connection with its 100% stock-for-stock merger with…

Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective provider payment capabilities for episodes of care, supporting the…

Davis Polk is advising the special committee of the board of directors of China Biologic Products Holdings, Inc. (“China Biologic”) in connection with the going-private acquisition of China…

Davis Polk is advising Novo Nordisk A/S on its $1.8 billion acquisition of Emisphere Technologies Inc. and related Eligen SNAC royalty stream obligations owed to MHR Fund Management LLC,…

Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The…

Davis Polk advised Coloplast A/S in connection with its strategic equity investment in Francis Medical, Inc.Coloplast A/S is a Danish medical device company that develops products and…

Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…